2002•Zhongguo yaoke daxue xuebaoRequires access

Studies on Anticoagulant and Antithrombotic Effects of Recombinant Hirudin-III

Yu Liu

Abstract

AIM The purpose is to study the secretory manufacture of recombinant hirudin Ⅲ(HⅧ) and its anticoagulant and antithrombotic effects. METHODS Inferior vena cava thrombosis model in rats and A V circulation \%in vivo\% in rats were used to study recombinant hirudin Ⅲ(HⅧ)′s anticoagulant and antithrombotic effects. RESLUTS The weight of inferior vena cava thrombosis was 21.30±7.35 and 10.40±16.20 mg after administrating recombinant hirudin Ⅲ 25 and 50 μg/kg; the weight of thrombosis in A V circulation was 21.5±5.3 mg and 15 3±3.6 mg after administrating recombinant hirudin Ⅲ 25 and 50 μg/kg. CONCLUSION The antithrombotic and anticoagulant activity of recombinant hirudin Ⅲ was different from that of placebo group significantly in statistics. It could be developed to make a new antithrombotic drug.

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Antithrombotic, Hirudin, Anticoagulant, Medicine, Inferior vena cava, Recombinant DNA, Anticoagulant drug, Thrombosis